NO3103802T3 - - Google Patents

Info

Publication number
NO3103802T3
NO3103802T3 NO15811341A NO15811341A NO3103802T3 NO 3103802 T3 NO3103802 T3 NO 3103802T3 NO 15811341 A NO15811341 A NO 15811341A NO 15811341 A NO15811341 A NO 15811341A NO 3103802 T3 NO3103802 T3 NO 3103802T3
Authority
NO
Norway
Application number
NO15811341A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3103802T3 publication Critical patent/NO3103802T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO15811341A 2014-06-24 2015-06-24 NO3103802T3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (fr) 2014-06-24 2015-06-24 Nouveau composé de pyrrolopyrimidine ou sel de celui-ci, composition pharmaceutique le contenant, en particulier agent pour la prévention et/ou le traitement de tumeurs etc. sur la base de l'effet inhibiteur de la nae

Publications (1)

Publication Number Publication Date
NO3103802T3 true NO3103802T3 (fr) 2018-04-07

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15811341A NO3103802T3 (fr) 2014-06-24 2015-06-24

Country Status (21)

Country Link
US (2) US9963456B2 (fr)
EP (1) EP3103802B1 (fr)
JP (1) JP6192741B2 (fr)
KR (1) KR101947289B1 (fr)
CN (1) CN106661031B (fr)
AU (1) AU2015281155B9 (fr)
BR (1) BR112016025835B1 (fr)
CA (1) CA2946833C (fr)
DK (1) DK3103802T3 (fr)
ES (1) ES2656772T3 (fr)
HU (1) HUE037266T2 (fr)
MX (1) MX2016015015A (fr)
MY (1) MY183327A (fr)
NO (1) NO3103802T3 (fr)
PH (1) PH12016502130A1 (fr)
PL (1) PL3103802T3 (fr)
PT (1) PT3103802T (fr)
RU (1) RU2658008C2 (fr)
SG (1) SG11201608441YA (fr)
TW (1) TWI605048B (fr)
WO (1) WO2015199136A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (fr) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018085833A2 (fr) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018089786A1 (fr) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Inhibiteurs d'atg7 et leurs utilisations
WO2018110591A1 (fr) * 2016-12-13 2018-06-21 ヤマサ醤油株式会社 Dérivé de 2'-désoxy-7-déazapurine nucléoside ayant une activité antivirale
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1848718E (pt) * 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
WO2007067559A2 (fr) * 2005-12-06 2007-06-14 Regents Of The University Of Minnesota Agents antibacteriens
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
JP2013541587A (ja) 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
US9233964B2 (en) 2011-01-07 2016-01-12 Leo Pharma A/S Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
EP2738873A4 (fr) * 2011-07-29 2015-04-01 Kuang Chi Innovative Tech Ltd Matériau composite artificiel et antenne constituée de matériau composite artificiel
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof

Also Published As

Publication number Publication date
KR20170016510A (ko) 2017-02-13
US9963456B2 (en) 2018-05-08
US20180162864A1 (en) 2018-06-14
US10174040B2 (en) 2019-01-08
RU2658008C2 (ru) 2018-06-19
JP6192741B2 (ja) 2017-09-06
TW201625629A (zh) 2016-07-16
PH12016502130B1 (en) 2016-12-19
KR101947289B1 (ko) 2019-02-12
EP3103802B1 (fr) 2017-11-08
PL3103802T3 (pl) 2018-02-28
PT3103802T (pt) 2017-12-11
AU2015281155A1 (en) 2016-11-03
HUE037266T2 (hu) 2018-08-28
WO2015199136A1 (fr) 2015-12-30
AU2015281155B9 (en) 2017-11-16
PH12016502130A1 (en) 2016-12-19
RU2016149319A3 (fr) 2018-06-18
CN106661031B (zh) 2019-07-23
CA2946833A1 (fr) 2015-12-30
EP3103802A1 (fr) 2016-12-14
JPWO2015199136A1 (ja) 2017-04-27
EP3103802A4 (fr) 2017-03-08
BR112016025835A2 (fr) 2017-08-15
CN106661031A (zh) 2017-05-10
BR112016025835B1 (pt) 2022-09-20
SG11201608441YA (en) 2016-11-29
MY183327A (en) 2021-02-18
TWI605048B (zh) 2017-11-11
US20170066772A1 (en) 2017-03-09
RU2016149319A (ru) 2018-06-18
MX2016015015A (es) 2017-02-27
CA2946833C (fr) 2019-03-05
AU2015281155B2 (en) 2017-07-13
ES2656772T3 (es) 2018-02-28
DK3103802T3 (en) 2017-12-11

Similar Documents

Publication Publication Date Title
BR112016023294A2 (fr)
BR112016018895A2 (fr)
BR112016016900A2 (fr)
BR112016017696A2 (fr)
BR112016017131A2 (fr)
BR112016016546A2 (fr)
BR112016018278A2 (fr)
BR112016016741A2 (fr)
BR112016017226A2 (fr)
BR112016016106A2 (fr)
BR112016018800A2 (fr)
BR112016017713A2 (fr)
BR112016017660A2 (fr)
BR112016017469A2 (fr)
BR112016018632A2 (fr)
BR112016017502A2 (fr)
BR112016018401A2 (fr)
BR112016017093A2 (fr)
RU2016149319A3 (fr)
BR112016018896A2 (fr)
BR112016016575A2 (fr)
BR112016017421A2 (fr)
BR112016018653A2 (fr)
BR112016017378A2 (fr)
BR112016016965A2 (fr)